Since RUNX3 is reportedly hypermethylated in various cancer types, including lung cancer62,63, we speculate that Wnt inhibitors, such as vantictumab and LGK974, which are currently in clinical trials for other cancer types, may be useful in the treatment of pan-negative cases. Here, RUNX3 is linked to cancer.